Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Phase 3

Completed

Conditions: Cardiovascular Disease
Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Dulaglutide

First Posted Date: 2011-07-15

Last Posted Date: 2019-10-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 9901

Registration Number: NCT01394952

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Londonderry, United Kingdom

A Study of LY2584702 in Participants With Advanced Cancer

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Drug: LY2584702

First Posted Date: 2011-07-14

Last Posted Date: 2019-01-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 34

Registration Number: NCT01394003

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Abemaciclib
Drug: Fulvestrant

First Posted Date: 2011-07-14

Last Posted Date: 2023-03-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 225

Registration Number: NCT01394016

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Antonio, Texas, United States
🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States

A Study of LY2228820 in Participants With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: LY2228820
Drug: Midazolam
Drug: Tamoxifen

First Posted Date: 2011-07-14

Last Posted Date: 2020-03-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 89

Registration Number: NCT01393990

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Metastatic Clear Cell Renal Cell Carcinoma

Interventions: Drug: LY2510924
Drug: Sunitinib

First Posted Date: 2011-07-11

Last Posted Date: 2019-07-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 110

Registration Number: NCT01391130

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States

A Study to Evaluate the Effect of Food on LY2216684

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: LY2216684

First Posted Date: 2011-07-08

Last Posted Date: 2018-11-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT01389765

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States

A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: LY2216684
Drug: Activated Charcoal

First Posted Date: 2011-07-08

Last Posted Date: 2019-01-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 22

Registration Number: NCT01389752

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

Phase 1

Completed

Conditions: Solid Tumor
Lymphoma, Malignant

Interventions: Drug: warfarin
Drug: enzastaurin

First Posted Date: 2011-07-06

Last Posted Date: 2020-07-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 13

Registration Number: NCT01388335

Locations: 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France

A Study of LY2979165 in Healthy Subjects

Phase 1

Completed

Conditions: Bipolar Disorder

Interventions: Drug: LY2979165
Drug: placebo

First Posted Date: 2011-06-28

Last Posted Date: 2012-06-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 102

Registration Number: NCT01383967

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore

A Study of LY2216684 in Healthy Participants

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: LY2216684
Drug: Placebo-matching LY2216684
Drug: Placebo-matching alcoholic beverage
Drug: Alcoholic beverage

First Posted Date: 2011-06-27

Last Posted Date: 2019-06-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 28

Registration Number: NCT01380691

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States

Home Terms & Conditions Privacy Policy